SCHEMBL1928641

SCHEMBL1928641

CC1(C#N)CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12360987 0.97 ALDH1A1 (0.52)
SCHEMBL860505 0.97
SCHEMBL16137665 0.97 ALDH1A1 (0.52)
SCHEMBL10029791 0.97 ALDH1A1 (0.52)
SCHEMBL14533550 0.97 ALDH1A1 (0.52)
SCHEMBL5125852 0.97 ALDH1A1 (0.52)
SCHEMBL12866832 0.97 ALDH1A1 (0.52)
SCHEMBL1930515 0.93
SCHEMBL19864591 0.89 ALDH1A1 (0.46)
SCHEMBL459723 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116874466-B N-substituted dioxocyclobutylamino-3-hydroxy-pyridinecarboxamides as CCR6 inhibitors PFIZER INC. (US) 2026-05-26 CN disclosed
EP-4695242-A1 NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF Meta Pharmaceuticals (HK) Limited (HK) 2026-02-18 EP disclosed
US-20260035335-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2026-02-05 US disclosed
US-20250313524-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2025-10-09 US disclosed
US-20250296920-A1 FORMULATIONS COMPRISING N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDE COMPOUNDS AND USES THEREOF PFIZER INC. (US) 2025-09-25 US disclosed
US-12312344-B2 N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors PFIZER INC. (US) 2025-05-27 US disclosed
EP-4522583-A2 PI3K ALPHA INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2025-03-19 EP disclosed
CN-119486992-A PI3K alpha inhibitors and methods of use thereof 传达治疗有限公司 2025-02-18 CN disclosed
WO-2025011610-A1 AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-01-16 WO disclosed
CN-119306790-A Amide derivative, composition and use thereof 深圳市塔吉瑞生物医药有限公司 2025-01-14 CN disclosed
EP-2151431-A1 AMIDE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2010-02-10 EP disclosed
EP-2143709-A1 AMIDE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2010-01-13 EP disclosed
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-15 US disclosed
WO-2009085072-A1 COMPOSITION COMPRISING CHELATING AGENTS CONTAINING AMIDOXIME COMPOUNDS EKC TECHNOLOGY, INC (US) 2009-07-09 WO disclosed
US-7479495-B2 N-heterocyclic inhibitors of TNF-α expression PHARMACOPEIA, INC. (US) 2009-01-20 US disclosed
US-7479495-B2 N-heterocyclic inhibitors of TNF-α expression PHARMACOPEIA, INC. (US) 2009-01-20 US disclosed
WO-2009004171-A2 1-BENZYLPYRAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-01-08 WO disclosed
US-6444677-B2 TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. PFIZER INC. 2002-09-03 US disclosed
EP-1106614-A1 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. (US) 2001-06-13 EP disclosed
EP-0160208-A1 3-(2,2-Tetramethylenepropyl)-1,3,5-triazine-2,4-diones BAYER AG (DE) 1985-11-06 EP disclosed